Background: Clinical studies have shown that the use of certain drugs can reduce disability. Access to prescription drugs varies across countries. Even when the total number of drugs launched in two countries is similar, the specific drugs that were launched, and the diseases those drugs are used to treat, may differ. Objective/Hypothesis: We test the hypothesis that the larger the relative number of drugs for a disease that were launched during 1982e2015 in a country, the lower the relative disability in 2015 of patients with that disease in that country, controlling for the average level of disability in that country and from that disease, and the number of patients with the disease and their mean age. Methods: We estimate two-way (by country and disease) fixed-effects models of several measures of disability for 31 diseases in eleven European countries using data from the Survey of Health, Ageing and Retirement in Europe and from other sources. Results: The estimates imply that drug launches during 1982e2015 reduced the probability of severe limitation in 2015 by 4.9 percentage points, from 21.8% to 16.9%; they reduced the probability of any limitation by 7.7 percentage points, from 61.1% to 53.4%; and they reduced the mean number of Activities of Daily Living limitations by about 29%. Drug launches also yielded a small increase in an index of quality of life and well-being. Conclusions: In general, the larger the number of drugs for a disease that were launched during 1982 e2015 in a country, the lower the average disability in 2015 of patients with that disease in that country, controlling for the average level of disability in that country and from that disease, and the number of patients with the disease and their mean age.
Introduction
Clinical studies have shown that the use of certain drugs can reduce disability. Nevitt et (2000) 1 showed that in postmenopausal women with preexisting vertebral fracture, alendronate therapy for 3 years reduced the number of days of bed disability and days of limited activity caused by back pain. Filippini et al. (2014) 2 demonstrated that etanercept, adalimumab, and infliximab reduced disability in rheumatoid arthritis patients, even those with a longstanding history and highly-active form of the disease. Andalo (2016) 3 showed that multiple sclerosis patients given alemtuzumab (first launched in 2001) were almost twice as likely to achieve an improvement in physical disabilities as those given interferon beta-1a (first launched in 1995). Access to prescription drugs varies across countries. Fig. 1 shows the number of new chemical entities (NCEs) that were launched in eleven European countries during the period 1982e2015. The average number of NCEs launched in the top 3 countries (709) was 42% higher than the number of NCEs launched in the bottom 3 countries (501). Even when country A had more launches than country B, country A may have had fewer drugs launched for some diseases. As shown in Fig. 2 , at least two more drugs were launched in Italy than in Spain for four diseases, and at least two fewer drugs were launched in Italy for three other diseases.
This study will empirically investigate two hypotheses about relative access to prescription drugs for different diseases in different countries. The first hypothesis is about the determinants of relative access. The hypothesis is that the greater the relative prevalence of a disease in a country, the larger the relative number of drugs for the disease that will be launched in the country. The second hypothesis is about the consequences of relative access. The hypothesis is that the larger the relative number of drugs for a disease that have been launched in a country, 1 the lower the relative disability of patients with that disease in that country, controlling for several other factors. As shown in Fig. 3 , relative disability from different diseases varies across countries: French people who had had chronic kidney disease and hip fractures were more likely to be severely limited than Germans, but French people who had had ulcers, breast cancer, and strokes were less likely to be severely limited than Germans.
Both of these hypotheses will be tested using a two-way, fixedeffects, cross-sectional research design, based on group-level data on 31 diseases in 11 countries derived from Wave 6 of the Survey of Health, Ageing and Retirement in Europe (SHARE) and other sources. The models we will estimate will include both country fixed effects and disease fixed effects, which control for the average level of disability (and the average number of drug launches) in each country and for each disease. 2 Several alternative (self-reported) measures of disability (and quality of life) will be analyzed, including the fraction of people with severe limitations or any limitations, and the number of activities of daily living limitations.
In the next section, we describe econometric models of the determinants and consequences of relative prescription drug access, and data sources and descriptive statistics. Empirical results are presented in Section III. Implications of the estimates are discussed in Section IV. Section V provides a summary and conclusions.
Methods

Model of the effect of disease prevalence on the number of drug launches
Previous studies have shown that both innovation (the number of drugs developed) and diffusion (the number of drugs launched in a country) depend on market size. Acemoglu and Linn (2004) 7 found "economically significant and relatively robust effects of 1 International differences in drug expenditure are not meaningful indicators of international differences in access to drugs due to substantial variation in drug prices. For example, in 2017 the price of the hepatitis C drug Harvoni was over 200 times as high in the U.S. as it was in Egypt. See Civio (2017) 4 and Lichtenberg (2010). 8 found that "countries with lower expected prices or smaller expected market size experience longer delays in new drug access, controlling for per capita income and other country and firm characteristics" (emphasis added). The hypothesis that the number of drug launches is influenced by market size can be investigated in a two-way fixed-effects framework by estimating the following equation:
where LAUNCHES_2006_2015 dc ¼ the number of drugs to treat disease d launched in country c during 2006e2015 PREV_2005 dc ¼ the number of patients in country c in 2005 who had ever been told by a doctor that they had disease d
Model of the effect of the number of drug launches on disability
The basic model we will estimate to investigate the effect of prescription drug access on disability is:
where Y dc is one of the following variables: PREV dc ¼ the number of people in country c in 2015 who said that a doctor ever told them that they had disease d Fig. 2 . Difference between number of drugs launched during 1982e2015 for 7 diseases in Italy and Spain. 3 The CASP index was designed to cover the active and beneficial experiences of later life rather than simply focus on the medical and social care issues that had traditionally been seen to typify ageing research. The scale is composed of 4 subscales, the initials of which make up the acronym: Control, Autonomy, Self- A person is considered to have a disease if he or she said that a doctor had ever told them that they had the disease. Sixty percent of individuals in the sample who had at least one disease had more than one disease. From the survey, we know whether someone was disabled, but we don't know which medical conditions caused the disability. 6 We will account for this in the following way: an individual with N diseases will contribute N observations (one for each disease), but each observation will be given a weight of (1/N). 7 Eq.
(2) will be estimated by weighted least squares; the disturbances will be clustered within countries or within diseases. The following weights will be used: 11 documented "high prevalence of disability among those who are obese." 6 In contrast, the U.S. Medical Expenditure Panel Survey provides some information about the specific causes of activity limitations. 7 Weighting the observations in this way does not have a significant impact on the estimates of eq. (2). 8 The first two weights are based on the fact that the variance of the binomial distribution with parameters n and p (where n is the number of trials and p is the "success" probability) is n * p * (1 -p).
F.R. Lichtenberg / Disability and Health Journal xxx (xxxx) xxxchemical entities used to treat disease d launched in country c during 1982e2015. 9 The launch of a drug in a country indicates that patients could have been treated with that drug, not necessarily that patients were treated with that drug. We would prefer to estimate models in which the explanatory variables measured the drugs actually used to treat patients, by disease and country. We have 2015 data on the utilization of each drug in each country. However, many drugs have multiple indicationsd48% of drugs have 2 or more indications (causes of disability), and 8% of drugs have 6 or more indicationsdand our data do not enable us to determine how often each drug was used for each of its indications. In eq. (2), the number of drugs launched at different times during 1982e2015 (e.g. before and after 2000) are constrained to have equal effects on disability in 2015. It is possible, however, that the effect of more recently-launched drugs could differ from the effect of drugs launched longer ago. The effect of a drug's launch on disability is likely to depend on both the quantity and the quality (or effectiveness) of the drug. Indeed, it is likely to depend on the interaction between quantity and quality: a quality improvement will have a greater impact on disability if drug utilization (quantity) is high. Drugs launched in different periods are likely to vary (in opposite ways) with respect to both quantity (in 2015) and quality. Newer drugs are likely to be of higher quality than older drugs. 10 On the other hand, utilization of new drugs tends to be much lower than utilization of old drugs. 11 To allow for the possibility that drugs launched at different times during 1982e2015 had different effects on disability in 2015, we will also estimate two more general versions of eq. (2). 12 In the first version, we differentiate between the number of launches in 3 periods, by replacing (b 0-33 LAUN-CHES_1982_2015 dc ) in eq. (2) The disease prevalence variable (ln(PREV dc )) is included as a regressor in eq. (2) to control for potential variation in disease screening intensity or awareness. Suppose that the severity of a disease is normally distributed, as depicted in Fig. 4 . If disease screening/awareness is low, only the most severe cases (those with severity S > S 0 ) will be detected and reported, and mean disability from the disease will be high. If disease screening/awareness is high, less severe cases (those with severity S > S 1 ) will be detected and reported, and mean disability from the disease will be lower. Hence one would expect that the higher the relative reported prevalence of a disease, the lower the relative mean disability from the disease. As discussed above, higher (true or measured) disease prevalence is also likely to cause more drug launches. Therefore, as shown in Fig. 5 , failure to control for prevalence could bias estimates of the drug launch coefficients away from zero. On the other hand, controlling for prevalence may make our estimates of the Fig. 4 . Effect of disease screening/awareness on measured prevalence and mean severity. 9 More than a dozen studies published in high-quality peer-reviewed journals (e.g. Refs. 6, 12e14) have examined the impact of drug launches on mortality. Also, a study based on U.S. data 15 showed that growth in the mean number of prescriptions for new (post-1990) drugs consumed for a medical condition is strongly related to growth in the (lagged) cumulative number of drugs launched for the condition and not related to changes in the socioeconomic status (income, education, or race) of people with the condition. 10 Grossman and Helpman (1993) 16 argued that "innovative goods are better than older products simply because they provide more 'product services' in relation to their cost of production." Bresnahan and Gordon (1996) 17 stated simply that "new goods are at the heart of economic progress," and Bils (2004) 18 said that "much of economic growth occurs through growth in quality as new models of consumer goods replace older, sometimes inferior, models." As noted by Jovanovic and Yatsenko (2012), 19 in "the SpenceeDixiteStiglitz tradition … new goods [are] of higher quality than old goods." 11 For example, a previous study [6] showed that mean utilization of a cancer drug is about twice as high 5e9 years after launch as it was 0e4 years after launch. 12 However, our ability to distinguish between the effects of launches in different periods will be limited by (negative) serial correlation in drug launches, which results in multicollinearity between the number of launches in different periods. This serial correlation is evident from estimates of the following model: drug launch coefficients to be conservative. Targeted efforts and programs to reduce disease burden are likely to depend on disease prevalence, so controlling for prevalence will also control at least to some extent for the effects of those efforts and programs on disability.
The fixed effects in eq. (2) control for many unobserved potential determinants of disability. The disease fixed effects (a d 's) control for the fact that (for example) average disability from chronic kidney disease is higher than average disability from ulcers. The country fixed effects (p c 's) control for a country's attributes (e.g. its average income, educational attainment, and health care expenditure) to the extent that they have similar effects on disability from different diseases. 13 
Data sources and descriptive statistics
Data on disability were obtained from Wave 6 of the Survey of Health, Ageing and Retirement in Europe (SHARE), a multidisciplinary and cross-national panel database of micro data on health, socio-economic status and social and family networks of more than 120,000 individuals aged 50 or older. 20 The fieldwork of Wave 6 was completed in November 2015. Although SHARE covers 27 European countries and Israel, data on drug launches since 1982 were available for only eleven of those countries. 14 Summary statistics, by country, are shown in Table 1 . The total number of survey respondents in the eleven countries was 45,592, and their mean age was 67.8. The average number of medical conditions reported (including persons with no medical conditions) was 1.6. Thirteen percent of respondents indicated that they were severely limited, and 43% indicated that they had either a severe or mild limitation. The mean number of ADL and IADL limitations reported were 0.3 and 0.5, respectively. Summary statistics, by medical condition, are shown in Table 2 . Two cardiovascular conditions (I10 hypertension and E78 high cholesterol) were the most prevalent by far. However, disability associated with these conditions was lower than disability associated with other medical conditions. Ten percent of people with either of the two cardiovascular conditions were severely limited, whereas 17% of people with all conditions were severely limited. Therefore, although the number of people who had hypertension was almost twice as great as the number who had osteoarthritis, the weight given to hypertension in the ln(limit_severe% dc /(1 e limit_severe% dc )) model is only 28% larger than the weight given to osteoarthritis.
Data on the number of SHARE Wave 6 respondents who reported that they had each medical condition, by country, are shown in Appendix Table 1 .
Data on drug launch years, by molecule and country, were obtained from the IMS Health New Product Focus database. Data on the indications of each drug were obtained from the Th eriaque database. 21, 15 Data on the number of drugs launched during 1982e2015, by country and medical condition, are shown in Table 3 .
Results
Estimate of model of the effect of disease prevalence on the number of drug launches 15 The Th eriaque database provides data on labeled indications, not on unlabeled indications. To the extent that drugs are used off-label, the drug launch variables in eq. (2) are measured with error. If this measurement error is random, it is likely to bias estimates of the drug launch coefficients towards zero.
finding is broadly consistent with the notion that "misery loves company" (Lichtenberg and Waldfogel (2009) 22 ): the relative number of drugs launched for a disease in a country is higher when the relative prevalence of that disease is greater.
Estimates of model of the effect of the number of drug launches on disability
Estimates of the model of the effect of the number of drug launches on disability (eq. (2)) are presented in Table 4 . All models include disease fixed effects and country fixed effects, but to conserve space, estimates of these parameters are not shown in Table 4 . Complete estimates of one model (the model of the logodds of severe limitation) are shown in Appendix Table 2 .
In column 1 of Table 4 , the dependent variable is the log-odds of severe limitation. The coefficient on LAUNCHES_1982_2015 is negative and highly significant (p-value ¼ .004), which signifies that the larger the relative number of drugs launched during 1982e2015, the lower were the relative odds of severe limitation in 2015. The impact of drug launches on the log-odds of severe limitation (b 0-33 * mean(LAUNCHES_1982_2015 dc )), was À0.317. This signifies that drug launches during the entire 1982e2015 period reduced the log-odds of severe limitation in 2015 by 27% (¼ 1 e exp(-0.317)). The coefficient on ln(PREV) is negative and significant; this may be due to the effects of disease screening/awareness on measured prevalence and mean disability. The coefficient on AGE_MEAN is positive and significant; older people are more likely to have severe limitations. The coefficient on OVERWEIGHT% is also positive and significant, but the coefficient on OBESE% is insignificant.
In column 2 of Table 4 , the dependent variable is the log-odds of any (severe or mild) limitation. The estimates of this model are very similar to the estimates in column 1. Drug launches during the entire 1982e2015 period are also estimated to have reduced the log-odds of any limitation in 2015 by 27%.
In column 3, the dependent variable is the mean number of ADL limitations. Drug launches during the 1982e2015 period are estimated to have reduced the mean number of ADL limitations in 2015 by 0.136. The mean number of ADL limitations among people with at least one medical condition was 0.341. This implies that drug launches during the entire 1982e2015 period reduced the mean number of ADL limitations in 2015 of people with at least one medical condition by 29% (¼ 0.136/(0.341 þ .136)).
In column 4, the dependent variable is the mean number of IADL limitations. The estimates indicate that drug launches did not have a statistically significant effect on mean number of IADL limitations.
In column 5, the dependent variable is the mean CASP index of quality of life and well-being. The estimate of the drug launch coefficient is positive and marginally significant (p-value ¼ .075). The mean CASP index among people with at least one medical Table 4 Estimates of model of the effect of the number of drug launches and other variables on disability (eq. (2)). Estimates in bold are statistically significant (p-value < .05).
Eq. (2):
condition was 36.58, so this implies that drug launches during the entire 1982e2015 period increased the mean CASP index of people with at least one medical condition by 1.6% (¼ 0.576/36.58).
As discussed above, to allow for the possibility that drugs launched at different times during 1982e2015 had different effects on disability in 2015, we also estimated two more general versions of eq. (2), in which we differentiated between the number of launches in 3 or 4 periods. Appendix Table 3 provides a comparison of the estimated impacts of new drug launches on disability in the three different versions of the model. The magnitudes and significance of the estimated effects on each of the disability measures are almost identical in the three models. This may be attributable to multicollinearity between the number of launches in different periods. A multivariate regression model with collinear predictors can indicate how well the entire bundle of predictors predicts the outcome variable, but it may not give valid results about any individual predictor, or about which predictors are redundant with respect to others. 23 
Discussion
Estimates of the effects of 1982e2015 drug launches on the mean 2015 disability of people with at least one medical condition are summarized in Table 5 . The first column shows the actual mean values, which are approximately equal to the values for 31 medical conditions combined in Table 2 . The second column shows the counterfactual mean value, under the (admittedly unrealistic) assumption that no drugs had been launched during 1982e2015. The third column shows the difference between the actual and counterfactual means, i.e. the estimated effect of 1982e2015 drug launches on the disability measure. The estimates imply that drug launches during 1982e2015 reduced the probability of severe limitation in 2015 by 4.9 percentage points, from 21.8% to 16.9%. They reduced the probability of any limitation in 2015 by 7.7 percentage points, from 61.1% to 53.4%. 16 Verropoulou and Tsimbos (2017) 24 11, 13 has demonstrated that new drug launches have also provided those benefits. Our analysis is subject to several limitations. Our measure of access to prescription drugs (the number of drugs previously launched in a country) is imperfect. Launch of a drug is a necessary condition for access, not a sufficient condition. Our drug launch data are left-censoreddonly drugs launched anywhere in the world after 1981 are captured. Our analysis did not account for offlabel uses of a drug. Our drug indications data were obtained from a French database, and some drugs launched in other countries have not been launched in France. Our estimates control for the effects on disability of a country's overall health system and macroeconomic conditions, to the extent that those effects don't vary across diseases, but those effects might vary across diseases. The effects of targeted efforts and programs to reduce disease burden may be imperfectly controlled for by including disease prevalence in the disability models. Our data enabled us to measure the average disability of people with a medical condition, not the average disability of people caused by a medical condition. Future research may enable these limitations to be superseded.
Conclusion
Access to prescription drugs varies across countries. Even when the total number of drugs launched in two countries is similar, the specific drugs that were launched, and the diseases those drugs are used to treat, may differ.
We used data on 31 diseases in eleven European countries, partially derived from the Survey of Health, Ageing and Retirement in Europe, to test the hypothesis that the larger the relative number 
